Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2021 May 8;48(12):3940–3950. doi: 10.1007/s00259-021-05386-0

Table 2.

Univariable PFS analysis for PET and clinical parameters, multivariable analysis for PFS in all 53 patients

Univariable Models Multivariable Model
Characteristic HR1 95% CI1 p-value Characteristic HR1 95% CI1 p-value
SUVmax 1.04 1.01, 1.07 0.01
sumSUVmax 1.02 1.01, 1.03 <0.001 sumSUV max (for 5 units) 1.09 1.04, 1.14 <0.001
log-MTV 1.16 0.96, 1.40 0.13
log-sumMTV 1.19 0.99, 1.44 0.06
log-TLG 1.1 0.97, 1.25 0.11
log-sumTLG 1.12 0.99, 1.26 0.07
Age 0.99 0.96, 1.01 0.35
ECOG 0.90
 0 Ref.
 1 1.13 0.51, 2.51
 2 1.29 0.43, 3.89
Treatment 0.01 Treatment 0.02
 Combination Ref.  Combination Ref.
 Single agent 3.09 1.18, 8.09  Single agent 2.73 1.03, 7.25
MYD88 0.76
 Mutated Ref.
 Wild type 0.9 0.44, 1.84
CD79B 0.73
 Mutated Ref.
 Wild type 1.14 0.55, 2.35
N lesions 0.08
 0 Ref.
 1 1.32 0.55, 3.15
 2+ 2.78 1.11, 7.00
log-Total tumor volume (cm3) 1.16 0.99, 1.35 0.05
1

HR = Hazard Ratio, CI = Confidence Interval